{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:52:17Z","timestamp":1780548737672,"version":"3.54.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","award":["Translational Research Fellowship"],"award-info":[{"award-number":["Translational Research Fellowship"]}],"id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00432-019-03071-2","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T15:56:39Z","timestamp":1576511799000},"page":"449-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series"],"prefix":"10.1007","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-3418","authenticated-orcid":false,"given":"Christoph","family":"Oing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hentrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Gl\u00e4ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Dieing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie Rodrigues","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,14]]},"reference":[{"key":"3071_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.044","author":"P Albers","year":"2015","unstructured":"Albers P et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.044","journal-title":"Eur Urol"},{"issue":"3","key":"3071_CR100","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/annonc\/mdm526","volume":"19","author":"C Bokemeyer","year":"2008","unstructured":"Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, B\u00f6hlke I, Kollmannsberger C; German Testicular Cancer Study Group (2008) Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19(3):448\u2013453","journal-title":"Ann Oncol"},{"key":"3071_CR2","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00432-016-2204-6","volume":"142","author":"M Gerwing","year":"2016","unstructured":"Gerwing M et al (2016) Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. J Cancer Res Clin Oncol 142:1979\u20131994","journal-title":"J Cancer Res Clin Oncol"},{"key":"3071_CR3","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1200\/jco.2009.26.8128","volume":"28","author":"International Prognostic Factors Study G","year":"2010","unstructured":"International Prognostic Factors Study G et al (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28:4906\u20134911. https:\/\/doi.org\/10.1200\/jco.2009.26.8128","journal-title":"J Clin Oncol"},{"key":"3071_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2016.1195808","volume":"25","author":"C Oing","year":"2016","unstructured":"Oing C, Kollmannsberger C, Oechsle K, Bokemeyer C (2016) Investigational targeted therapies for the treatment of testicular germ cell tumors. Expert Opin Investig Drugs 25:1033\u20131043. https:\/\/doi.org\/10.1080\/13543784.2016.1195808","journal-title":"Expert Opin Investig Drugs"},{"key":"3071_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ctrv.2018.10.007","volume":"71","author":"C Oing","year":"2018","unstructured":"Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J (2018) Palliative treatment of germ cell cancer. Cancer Treat Rev 71:102\u2013107. https:\/\/doi.org\/10.1016\/j.ctrv.2018.10.007","journal-title":"Cancer Treat Rev"},{"issue":"168","key":"3071_CR7","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.urolonc.2015.11.007","volume":"34","author":"C Seidel","year":"2016","unstructured":"Seidel C et al (2016) Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care-registry data from an outcomes research project of the German testicular cancer study group. Urol Oncol 34(168):e121\u2013e168. https:\/\/doi.org\/10.1016\/j.urolonc.2015.11.007","journal-title":"Urol Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-03071-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-03071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T00:47:40Z","timestamp":1607820460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-03071-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,14]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["3071"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-03071-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,14]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Protocol, CRF, and patient consent to retrospective data collection on palliative treatment of GCT and analysis of outcomes were approved by the Ethical Board of the Hamburg Chamber of Physicians (Ref No. 5423). Off-label use of cabazitaxel outside of a clinical trial was conducted after obtaining written informed consent in accordance with the Declaration of Helsinki 2013, \u00a737. Patients were informed about the investigational nature of this treatment and the underlying preclinical and clinical rationale as well as about pseudonymised data collection on treatment efficacy. No identifying information of individual patients is included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}